<DOC>
	<DOCNO>NCT01876381</DOCNO>
	<brief_summary>To investigate safety , pharmacokinetics , pharmacodynamics , efficacy OPC-41061 patient chronic renal failure undergo hemodialysis hemodiafiltration use variable , daily urine volume increase interval body weight hemodialysis hemodiafiltration , 4-day intermittant administration ( exclude day hemodialysis hemodiafiltration ) dose fixed dose-escalation period</brief_summary>
	<brief_title>A Phase 2 , Multi-center , Open-label , Dose-finding Trial Investigate Efficacy , Safety , Pharmacokinetics , Pharmacodynamics OPC-41061 Patients With Chronic Renal Failure Undergoing Hemodialysis Hemodiafiltration</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients chronic renal failure undergo hemodialysis hemodiafiltration three time week Subjects age 20 80 , inclusive ( time inform consent ) Subjects inpatient admit trial site duration trial period Subjects , together partner , able practice one specify contraceptive method 4 week final trial drug administration Patients capable provide write informed consent trialrelated procedure perform Subjects complication urinary impairment due urinary tract stricture , urinary calculus , tumor urinary tract , cause Subject daily urine volume le 500 mL Subject Cardiac function NYHA class 4 Subjects serious ischemic heart disease , judge investigator subinvestigator inappropriate inclusion trial Subjects serious arrhythmia , judge investigator subinvestigator inappropriate inclusion trial Subjects concomitantly undergo peritoneal dialysis Subjects ascites due cirrhosis cancer , requring medical treatment Subjects follow medical history : History cerebrovascular disorder coronary artery disease within 4 week prior inform consent History hypersensitivity idiosyncratic reaction benzazepine derivative mozavaptan hydrochloride benazepril hydrochloride Subjects follow abnormal laboratory value : Hemoglobin low 8.0 g/dL , total bilirubin high 3.0 mg/dL , ALT ( GPT ) AST ( GOT ) 2 time upper limit reference range trial site , serum sodium high upper limit reference range trial site , serum sodium lower 125mEq/L Subjects serum potassium high 6.0mEq/L abnormal finding inappropriate inclusion trial observe 12lead ECG Subjects unable sense thirst difficulty fluid food intake Subjects participate clinical trial postmarketing clinical study within 4 week prior inform consent Female subject pregnant , possibly pregnant , nursing , plan become pregnant trial period Subjects otherwise judge investigator subinvestigator inappropriate inclusion trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>